My Site Group

Keytruda Market Share

The Keytruda Market share is a reflection of its dominant position within the PD-1/PD-L1 inhibitor class. Manufactured by Merck & Co., Inc., Keytruda holds a leading market share, particularly in the United States and Europe. Its market leadership is attributed to its first-mover advantage in several key indications, such as non-small cell lung cancer (NSCLC) and melanoma, and a broad portfolio of approved uses. Merck's aggressive and successful clinical development program has allowed Keytruda to outpace its primary competitor, Bristol-Myers Squibb's Opdivo (nivolumab), in terms of overall sales and market share in many regions.

However, the market is not a monopoly. Keytruda faces fierce competition from other PD-1/PD-L1 inhibitors, which also hold significant market shares in specific cancer types. For instance, Opdivo maintains a strong presence, particularly in melanoma and renal cell carcinoma. Other key players include Roche with its drug Tecentriq (atezolizumab) and AstraZeneca with Imfinzi (durvalumab). These companies compete by securing approvals for new indications and developing unique combination therapies. The market share dynamics are constantly shifting based on clinical trial outcomes, new regulatory approvals, and strategic partnerships. The impending patent expiration of Keytruda in 2028 is expected to significantly impact its market share, as lower-cost biosimilars enter the market